Home » Dengue – Pipeline Insights

Dengue – Pipeline Insights

Dengue – Pipeline Insights, Recent Developments, Major Players and Review
Report Book

Published Date: June 2022
Category: Pharmaceuticals
Report ID: 60577
Report Format: PDF
No of Pages: 190

Rating: Credence Reports

Dengue fever is a virus-borne illness caused by mosquitos carrying one of the dengue viruses. This viral is prevalent in regions such as Asia Pacific, South America, and the Pacific Islands. Dengue fever is estimated to affect at least 400 million people worldwide each year, according to the Centers for Disease Control and Prevention (CDC). When people with asthma, diabetes, or other chronic conditions contract dengue fever, the infection can be fatal.

Dengue transmission has spread across more geographical areas in recent years, with all four dengue virus serotypes (DENV-1–4) now circulating in Asia, Africa, and the Americas, a stark contrast to the situation 20 or 30 years ago. Several novels or validated dengue control and prevention methods and strategies have been created recently and are now available to public health practitioners and doctors.

Report Key Takeaways

Recommended Medications/Treatments for Dengue

  • Despite the lack of vaccines or medications, severe sickness conditions can be effectively controlled by following the proper guidelines and undergoing vigorous intravenous rehydration therapy early.
  • Patients should obtain a fluid replacement to avoid hemodynamic instability, blood pressure narrowing, and hypotension. Other problems, such as significant hemorrhage, disseminated intravascular coagulation, multiple organ failure, and respiratory failure due to non-cardiogenic pulmonary edema, can be avoided with prompt resuscitation.
  • The only treatment for uncomplicated dengue fever is supportive care, which includes lots of oral fluids during the fever and paracetamol, the daily dosage of which should not be exceeded to avoid intoxication, which is mainly connected to liver function.

Recent Developments Related to Dengue

  • The National Institute of Allergy and Infectious Diseases (NIAID) has announced a $577 million grant to create nine Antiviral Drug Discovery Centers for Pandemic Pathogens. The AViDD centers will conduct multidisciplinary research to develop promising COVID-19 antivirals, particularly those taken by patients in an outpatient setting, and other antivirals targeting specific viral families with a high potential to cause a pandemic in the future, according to the NIAID announcement. The targeted viruses include Dengue, Ebola, enteroviruses, yellow fever, and Zika.
  • A combined AI research project between BenevolentAI and the Drugs for Neglected Disease Initiative (DNDi) to combat dengue fever has begun. In a non-commercial collaboration with DNDi, the company’s AI-enhanced technique will be utilized to identify several possible biological targets and medication repurposing candidates that could aid in the prevention of severe dengue.
  • SingHealth researchers are testing a medication to treat dengue fever. The novel investigational drug acts by blocking the interaction of two dengue virus proteins known as NS3 and NS4B. Furthermore, 150 participants who have been infected with dengue will receive standard dengue treatment as part of the Deng-I trial.

Major Players Working on Dengue

Some leading companies engaged in researching and developing advanced medicines and treatments for dengue include Merck Sharp & Dohme, Takeda Pharmaceuticals, GlaxoSmithKline, Zydus Cadila, GeneOne Life Science Inc., Sanofi Pasteur, and Janssen Pharmaceutica NV.

Key Reasons to Purchase This Report

  • The pipeline insight covers the commercial evaluation and the clinical assessment of pipeline pharmaceuticals for the target disease.
  • The pipeline insight competitive landscape contains detailed information on significant companies and a section dedicated to the most recent events, such as strategic developments and license updates.
  • The pipeline insights give a more comprehensive picture of dengue medicines, including all stages of clinical trials and a treatment’s success rate.

Frequently asked questions :

What are the common symptoms of dengue?

When you first receive DENV, the symptoms are usually moderate, but if you get another infection with a different version of DENV, your risk of serious problems increases.

What are the factors that lead to dengue?

One of four dengue viruses causes dengue disease. When you are bitten by a mosquito carrying the dengue virus, the virus can enter your bloodstream and replicate itself.

How is the diagnosis of dengue performed?

A blood test is used to diagnose dengue fever. Your healthcare provider will draw blood from a vein and send it to a laboratory to check for symptoms of the dengue virus.

What are the complications associated with dengue?

Dengue fever can lead to a more deadly form of the disease known as dengue hemorrhagic fever in a tiny percentage of patients.

What is the infection rate of dengue?

According to studies, about 400 million people are infected with dengue fever each year, but the majority of them (almost 80%) have no symptoms.

Download Sample Report

Have a question?

Market Research Analyst

Don’t settle for less – trust Ishika to help you find the best solution.

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –


+91 8085 89 5002


24/7 Research Support

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN